Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.

Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update. Expert Opin Emerg Drugs. 2020 May 04;: Authors: AlShimemeri S, Fox SH, Visanji NP Abstract Introduction: Prolonged treatment with l-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of uncontrolled movements (L-DOPA-induced dyskinesias (LID)) in Parkinson's disease (PD). There is currently only a single approved drug for the treatment of LID, a long-acting preparation of the NMDA antagonist, amantadine, that has variable benefit and side-effects. Therefore, new treatments for LID remains an unmet in PD.Areas covered: We review the current strategies for the management of LID; the pathogenic mechanisms underlying the development of LID, which provides rationale for clinical trials of novel targets for LID and provide a review of phase II/III trials for emerging drugs for LID, with either positive results, or ongoing studies, reported between Jan 2014 - Dec 2019.Expert opinion: There are several ongoing studies for agents that showed possible benefit at phase Ib/IIa for reducing LID. However, there are no new positive phase III double blind randomised controlled clinical trial (DBRCT) for emerging treatments for LID. Generating better preclinical models, more precise recruitment tools and better outcome measures remain a priority. The pharmacology of drugs investigated for LID may be too selective, therefore evaluating combinations of drugs is worthy o...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research